Эффективность и безопасность биоаналога ритуксимаба (Ацеллбия®) при ревматоидном артрите в качестве "первого" генно-инженерного биологического препарата: результаты клинического исследования III фазы (ALTERRA)

Автор: Насонов Е.Л., Мазуров В.И., Зонова Е.В., Князева Л.А., Марусенко И.М., Несмеянова О.Б., Плаксина Т.В., Шаповалова Ю.С., Иливанова Е.П., Кречикова Д.Г., Петроченкова Н.А., Решетько О.В., Денисов Л.Н., Гордеев И.Г., Давыдова А.Ф., Еремина Н.А., Земерова Е.В., Иванова Т.Б., Кастанаян А.А., Покровская Т.Г., Смакотина С.А., Смолярчук Е.А., Артемьева А.В., Иванов Р.А., Усачева Ю.В., Черняева Е.В.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Оригинальные исследования

Статья в выпуске: 4 т.55, 2017 года.

Бесплатный доступ

Российской биотехнологической компанией «БИОКАД» разработан препарат химерных моноклональных антител к CD20 (BCD-020, Ацеллбия®) являющийся биоаналогом препарата ритуксимаб (РТМ; Мабтера®, Ф. Хоффманн-Ля Рош Лтд., Швейцария). В последние годы получены данные о возможности применения РТМ в более низких дозах, чем в стандартных рекомендациях и инструкциях, касающихся применения данного препарата. Это послужило основанием для проведения исследования BCD-020-4/ALTERRA (ALTErnative Rituximab regimen in Rheumatoid Arthritis), целью которого явилось изучение эффективности и безопасности применения Ацеллбия® (в дозе 600 мг дважды с интервалом 2 нед) в качестве «первого» ГИБП для лечения активного ревматоидного артрита (РА), резистентного к терапии метотрексатом (МТ). В исследование было включено 159 пациентов в возрасте от 18 до 80 лет с активным РА. Через 24 нед число больных, достигших 20% улучшения по критериям Американской коллегии ревматологов (ACR), составило в группе Ацеллбия® + МТ 65,7%, а в группе плацебо (ПЛ) + МТ - 29,4% (р

Еще

Ревматоидный артрит, ритуксимаб, ацеллбия®, мабтера

Короткий адрес: https://readera.org/14945833

IDR: 14945833   |   DOI: 10.14412/1995-4484-2017-351-359

Список литературы Эффективность и безопасность биоаналога ритуксимаба (Ацеллбия®) при ревматоидном артрите в качестве "первого" генно-инженерного биологического препарата: результаты клинического исследования III фазы (ALTERRA)

  • Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331
  • Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38 DOI: 10.1016/S0140-6736(16)30173-8
  • Catrina AI, Svensson CI, Malmströ m V, et al. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Immunol. 2017;13(2):79-86 DOI: 10.1038/nrrheum.2016.200
  • Moura RA, Fonseca JE. To B or not to B the conductor of rheumatoid orchestra. Clin Rev Allerg Immunol. 2012 Dec;43(3):281-91 DOI: 10.1007/s12016-012-8318-y
  • Leandro M. B cells and rheumatoid factors in autoimmunity. Int J Rheum Dis. 2015;18:379-81 DOI: 10.1111/1756-185X.12690
  • Tan EM, Smolen JS. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med. 2016;213:1937-50 DOI: 10.1084/jem.20160792
  • Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017 Jun;39(4):437-46 DOI: 10.1007/s00281-017-0627-z
  • Bugatti S, Bogliolo L, Montecucco C, Manzo A. B cell autoimmunity and bone damage in rheumatoid arthritis. Reumatismo. 2016;68(3):117-125 DOI: 10.4081/reumatismo.2016.914
  • Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human antibody to CD20. Blood. 1994;83:435-45.
  • Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 552 с.
  • Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheum Ther. 2015;2:99-111 DOI: 10.1007/s40744-015-0016-9
  • Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. С. 55-93
  • Bugatti S, Vitolo B, Caporali R, et al. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. Biomed Res Int. 2014;2014:681678 DOI: 10.1155/2014/681678
  • Seyfizadeh N, Seyfizadex N, Hasenkamp J, Huerta-Yepez S. A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Clin Rev Oncol Hematol. 2016;97:275-90 DOI: 10.1016/j.critrevonc.2015.09.001
  • De Lemos LLP, de Oliveira Costa J, de Avila Machado MA, et al. Rituximab for rheumatoid arthritis treatment: a systemic review. Rev Bras Reumatol. 2014;54:220-30 DOI: 10.1016/j.rbr.2013.08.001
  • Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356 DOI: 10.1002/14651858.CD007356.pub2
  • Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101-36 DOI: 10.1136/annrheumdis-2016-210708
  • Keyser FD, Hoffman I, Durez P, et al. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis Registry. J Rheumatol. 2014;41:1761-5 DOI: 10.3899/jrheum.131279
  • Harrold LR, Reed GW, Shewade A, et al. Effectiveness of rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: results from the CORRONA registry. J Rheumatol. 2015;42:1090-8 DOI: 10.3899/jrheum.141043
  • Wendler J, Burmester GR, Sörensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014;16:R80 DOI: 10.1186/ar4521
  • Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50 DOI: 10.1186/s13075-016-0951-z
  • Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77 DOI: 10.1136/annrheumdis-2016-210715
  • Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68:1-26 DOI: 10.1002/art.39489
  • Насонов ЕЛ, Каратеев ДЕ. Ревматоидный артрит. В кн.: Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. С. 17-57
  • Насонов ЕЛ, Зонова ЕВ, Иванова ОНидр. Результаты сравнительного клинического исследования III фазы препаратов ритуксимаба (Ацеллбия® и Мабтера®) при ревматоидном артрите (исследование BIORA). Научно-практическая ревматология. 2016;54(5):510-9
  • Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11:R131 DOI: 10.1186/ar2798
  • Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377-86 DOI: 10.1002/art.22019
  • Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8 DOI: 10.1002/art.30152
  • Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab; mechanisms of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917-25 DOI: 10.1136/ard.2007.080960
  • Bredemeier M, de Oliveira FK, Rocha CM. Low-versus High-dose rituximab for rheumatoid arthritis: a systemic review and metaanalysis. Arthritis Care Res. 2014;66:228-35 DOI: 10.1002/acr.22116
  • Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20 DOI: 10.1136/ard.2010.144998
  • Sacco JJ, Botten J, Macbeth F, et al. The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study. PLoSONE. 2010; 5(1):e8933 DOI: 10.1371/journal.pone.0008933
  • Van Vollenhoven RF. More or less rituximab? Biology and clinic, regulators and researchers. Arthritis Rheum. 2011;63:594-6 DOI: 10.1002/art.30154
  • Ferraccioli GF, Tolusso B, Gremese E. Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros anc cons? Arthritis Re Ther. 2016;18:126 DOI: 10.1186/s13075-016-1022-1
  • Porter D, van Melckebeke J, Dale J. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388(10041):239-47 DOI: 10.1016/S0140-6736(16)00380-9
  • Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400 DOI: 10.1002/art.21778
  • Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab. Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.
  • Mease P, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (D A N C E R) . Arthritis Rheum. 2005;52 Suppl:S138-9.
  • Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX inadequate responders (SERENE). Ann Rheum Dis. 2010;69:1629-35 DOI: 10.1136/ard.2009.119933
  • Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) . Arthritis Rheum. 2008;58 Suppl:S302.
  • Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition ofjoint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46 DOI: 10.1136/ard.2010.137703
  • Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX . Rheumatology (Oxford). 2010;49:i4.
  • Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20 DOI: 10.1002/acr.20419
  • Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7 DOI: 10.1136/annrheumdis-2011-200170
  • Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93 DOI: 10.1093/rheumatology/keq116
  • Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7 DOI: 10.1136/annrheumdis-2014-206015
  • Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression ofjoint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.
  • Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21 DOI: 10.1093/rheumatology/kep155
  • Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14 DOI: 10.1136/annrheumdis-2013-203480;63
  • McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7 DOI: 10.1093/rheumatology/ken103
  • Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93 DOI: 10.2217/ijr.14.18
  • Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14 DOI: 10.1002/art.30427
  • Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of ritux-imab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9 DOI: 10.1016/j.jbspin.2011.12.004
  • Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25 DOI: 10.4103/ijdvl.IJDVL_1078_14
  • Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17 DOI: 10.1111/ajd.12571
  • Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6 DOI: 10.1093/ndt/gfw251
  • Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51 DOI: 10.1111/ejh.12199
  • Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexam-ethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500 DOI: 10.1111/ejh.12102
  • Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus -a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4 DOI: 10.1093/rheumatology/ker176
  • Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502 DOI: 10.1136/annrheumdis-2012-201956
  • Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908 DOI: 10.1002/art.23059
  • Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12 DOI: 10.1136/ard.2009.109041
  • Manders SH, Kievit W, Adang E, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther. 2015 May 22;17:134 DOI: 10.1186/s13075-015-0630-5
  • Quartuccio L, di Bidino R, Ruggeri M, et al. Cost-effectiveness analysis of two rituximab retreatment regimens for longstandinf rheumatoid arthritis. Arthritis Care Res. 2015;67:947-55 DOI: 10.1002/arc22535
  • Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80 DOI: 10.1136/ard.2010.148759
  • Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;72:329-36 DOI: 10.1136/annrheumdis-2011-201117
  • Sneller MC, Zonghui H, Langford CA, et al. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835-42 DOI: 10.1002/art.34322
  • De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843-8 DOI: 10.1002/art.34331
  • Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-3 DOI: 10.1136/ard.2002.004929
  • Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multi-center cohort study and review of the literature. Autoimmun Rev. 2011;11(1):48-55 DOI: 10.1016/j.autrev.2011.07.005
  • Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford). 2016;55(7):1318-24 DOI: 10.1093/rheuma-tology/kew195
  • Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford). 2017 Apr 24;56(8):1348-57 DOI: 10.1093/rheumatology/kex072
Еще
Статья научная